Ascrinvacumab

• CAT Number: I042238
• CAS Number: 1463459-96-2
• Purity: ≥95%

Ascrinvacumab（Cat No.:I042238）is a monoclonal antibody designed to target and inhibit the activity of the amyloid beta protein, which accumulates abnormally in the brains of individuals with Alzheimer’s disease. By binding to amyloid beta, Ascrinvacumab aims to prevent the formation of amyloid plaques, which are associated with neurodegeneration and cognitive decline. This therapeutic approach is part of ongoing research into Alzheimer’s disease treatments, aiming to slow or halt disease progression. Clinical trials are investigating Ascrinvacumab’s safety, efficacy, and potential to improve cognitive function in Alzheimer’s patients, offering hope for new therapeutic options.